Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

NCT01870778 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

6600

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Heart Failure

Interventions

DRUG: RLX030
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals